The objective of this study was to assess the utility of forced inspiratory vital capacity (FIVC) to identify bronchodilator reversibility (BDR) for @entity1 with @entity3885 ( @entity3885 ) in relation to customary BDR criteria as defined by the American @entity1514 Society (ATS). Concurrent data analysis was used in an academic medical center setting. Two hundred @entity1 with @entity3885 (including chronic @entity3885 ) undergoing testing at the Pulmonary Function Laboratory at Cedars-Sinai Medical Center from January 1995 to December 1996 were identified. These 200 @entity1 were categorized into four grades of obstruction by ATS-defined forced expiratory volume in 1 sec (FEV1) criteria (severe, moderately severe, moderate, and mild). Each of these groups was further subdivided into equal subgroups according to the presence (+) or absence (-) of BDR. Inspiratory flow-volume loops and FIVC were analyzed for each of these subgroups. Of the @entity1 exhibiting BDR on the forced expiratory maneuver (FEM), FIVC correctly identified 53% of the cases. For @entity1 not exhibiting BDR on FEM, FIVC identified an additional 12 cases. In 72% of cases, the maximal FIVC was not obtained from the maximal FEM flow-volume loop. FIVC inspection of the data (which were already available from standard spirometric testing) identified a subgroup of @entity3885 @entity1 with BDR not appreciated by FEV1 or FVC criteria, which may respond to bronchodilator therapy. The maximal FIVC value should be obtained by manual inspection to identify the best inspiratory flow-volume loop.

Use of forced inspiratory vital capacity to identify bronchodilator reversibility in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1514 :: ('MESH:D013896', 'Disease') :: ['Thoracic'] @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstructive lung disease and asthma', 'OLD', 'obstructive lung disease']
@entity3885 :: (MESH:D008173,Disease) :: ['obstructive lung disease']
